Improving Response Inhibition in Parkinson’s Disease with Atomoxetine
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dopaminergic drugs remain the mainstay of Parkinson's disease therapy but often fail to improve cognitive problems such as impulsivity. This may be due to the loss of other neurotransmitters, including noradrenaline, which is linked to impulsivity and response inhibition. We therefore examined the effect of the selective noradrenaline reuptake inhibitor atomoxetine on response inhibition in a stop-signal paradigm. METHODS: This pharmacological functional magnetic resonance imaging study used a double-blinded randomized crossover design with low-frequency inhibition trials distributed among frequent Go trials. Twenty-one patients received 40 mg atomoxetine or placebo. Control subjects were tested on no-drug. The effects of disease and drug on behavioral performance, regional brain activity, and functional connectivity were analyzed using general linear models. Anatomical connectivity was examined using diffusion-weighted imaging. RESULTS: Patients with Parkinson's disease had longer stop-signal reaction times, less stop-related activation in the right inferior frontal gyrus (RIFG), and weaker functional connectivity between the RIFG and striatum compared with control subjects. Atomoxetine enhanced stop-related RIFG activation in proportion to disease severity. Although there was no overall behavioral benefit from atomoxetine, analyses of individual differences revealed that enhanced response inhibition by atomoxetine was associated with increased RIFG activation and functional frontostriatal connectivity. Improved performance was more likely in patients with higher structural frontostriatal connectivity. CONCLUSIONS: This study suggests that enhanced prefrontal cortical activation and frontostriatal connectivity by atomoxetine may improve response inhibition in Parkinson's disease. These results point the way to new stratified clinical trials of atomoxetine to treat impulsivity in selected patients with Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SMITH, S., & NICHOLS, T. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.061 · Cited by 5,250
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
On the ability to inhibit thought and action: a theory of an act of control
Logan, G. D., & Cowan, W. B. (1984) · Psychological Review · doi:10.1037/0033-295x.91.3.295 · Cited by 2,590
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Rubia, K., Russell, T., Overmeyer, S., Brammer, M. J., Bullmore, E. T., Sharma, T., Simmons, A., Williams, S. C. R., Giampietro, V., Andrew, C. M., et al. (2001) · NeuroImage · doi:10.1006/nimg.2000.0685 · Cited by 999 · cited 1×
“In contrast, a similar dose of atomoxetine had no effect (or even negative impact) on NoGo inhibition in healthy adults (20,21), which supports preclinical evidence of a neuropharmacologic distinction between restraint and cancellation type inhibition (22,23).”
ResultAssociation of dopamine agonist use with impulse control disorders in Parkinson disease
Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.969 · Cited by 662
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · cited 2×
“Go), was significantly reduced in PD-placebo compared with control subjects (disease effect, peak [56 16 12], t 5 3.”
BackgroundSelf-citationEagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548
Self-citationCools, R., Barker, R. A., Sahakian, B. J., & Robbins, T. W. (2003) · Neuropsychologia · doi:10.1016/s0028-3932(03)00117-9 · Cited by 516 · cited 1×
“Corrected pðrespondjsignalÞ 5 Observed pðrespondj signalÞ= 12Go omission rate ð Þ (1)”
Self-citationRobbins, T. W. (2007) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2007.2097 · Cited by 413 · cited 3×
“Noradrenergic systems may therefore support multiple executive processes, including control of motor and nonmotor impulsivity, response inhibition, and cognitive flexibility (21,55), which requires further evaluation for PD.”
BackgroundSelf-citationRobinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301487 · Cited by 359
Self-citationAtomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder
Chamberlain, S. R., del Campo, N., Dowson, J., Müller, U., Clark, L., Robbins, T. W., & Sahakian, B. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.003 · Cited by 288 · cited 5×
“While this could be due to type II error, it is also consistent with preclinical studies (20,21) reporting stop-signal modulation by noradrenaline (15,19) and NoGo modulation by serotonin (48).”
BackgroundMethodResultInfluentialSelf-citationAtomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255
McGaughy, J., Ross, R. S., & Eichenbaum, H. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.01.064 · Cited by 226 · cited 1×
“For example, attentional setshifting in the Wisconsin Card Sorting Test and Cambridge Neuropsychological Test Automated Battery intradimensional/ extradimensional set-shifting task are impaired by PD (49,50) and in animals with selective depletion of cortical noradrenaline (51,52) but can be relieved by atomoxetine (5…”
BackgroundBari, A., Eagle, D. M., Mar, A. C., Robinson, E. S. J., & Robbins, T. W. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1537-0 · Cited by 194
Self-citationPrefrontal and monoaminergic contributions to stop-signal task performance in rats
Bari, A., Mar, A. C., Theobald, D. E., Elands, S. A., Oganya, K. C. N. A., Eagle, D. M., & Robbins, T. W. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1543-11.2011 · Cited by 188
Self-citationLesions of the dorsal noradrenergic bundle impair attentional set-shifting in the rat
Tait, D. S., Brown, V. J., Farovik, A., Theobald, D. E., Dalley, J. W., & Robbins, T. W. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05612.x · Cited by 179
Self-citationEagle, D. M., Tufft, M. R. A., Goodchild, H. L., & Robbins, T. W. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0701-7 · Cited by 176
Self-citationThe Effect of Methylphenidate on Three Forms of Response Inhibition in Boys with AD/HD
Scheres, A., Oosterlaan, J., Swanson, J., Morein-Zamir, S., Meiran, N., Schut, H., Vlasveld, L., & Sergeant, J. A. (2003) · Journal of Abnormal Child Psychology · doi:10.1023/a:1021729501230 · Cited by 176
Rubia, K., Halari, R., Mohammad, A.-M., Taylor, E., & Brammer, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.018 · Cited by 171 · cited 1×
“Some studies of SSRT have used methylphenidate, which increases extracellular levels of both dopamine and noradrenaline, leaving it ambiguous as to whether dopamine or noradrenaline is responsible for the beneficial effect (11,24,60,61).”
Boonstra, A. M., Kooij, J. J. S., Oosterlaan, J., Sergeant, J. A., & Buitelaar, J. K. (2005) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390490515757 · Cited by 157
Newman, L. A., Darling, J., & McGaughy, J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1097-8 · Cited by 137
Bari, A., & Robbins, T. W. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3141-6 · Cited by 105 · cited 1×
“Studies that used more selective dopaminergic agents, such as levodopa and dopamine transporter blocker, have observed minor effects on SSRT, and patients with PD have poor response inhibition both on and off medication (12,30,55,62).”
BackgroundSelf-citationBari, A., & Aston-Jones, G. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.020 · Cited by 85
Neurochemical Enhancement of Conscious Error Awareness
Hester, R., Nandam, L. S., O'Connell, R. G., Wagner, J., Strudwick, M., Nathan, P. J., Mattingley, J. B., & Bellgrove, M. A. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4052-11.2012 · Cited by 68
Atomoxetine facilitates attentional set shifting in adolescent rats
Cain, R. E., Wasserman, M. C., Waterhouse, B. D., & McGaughy, J. A. (2011) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2011.04.003 · Cited by 55 · cited 1×
“For example, attentional setshifting in the Wisconsin Card Sorting Test and Cambridge Neuropsychological Test Automated Battery intradimensional/ extradimensional set-shifting task are impaired by PD (49,50) and in animals with selective depletion of cortical noradrenaline (51,52) but can be relieved by atomoxetine (5…”
Background
Cited by
Cam-CAN, Shafto, M. A., Tyler, L. K., Dixon, M., Taylor, J. R., Rowe, J. B., Cusack, R., Calder, A. J., Marslen-Wilson, W. D., Duncan, J., et al. (2014) · BMC Neurology · doi:10.1186/s12883-014-0204-1 · Cited by 707
Self-citationFractionating impulsivity: neuropsychiatric implications
Dalley, J. W., & Robbins, T. W. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.8 · Cited by 607
Self-citationLocus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 365
Self-citationRae, C. L., Hughes, L. E., Anderson, M. C., & Rowe, J. B. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3093-13.2015 · Cited by 274
Self-citationFox, H., Sofuoglu, M., & Sinha, R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114562464 · Cited by 30
“Both medications have been shown to improve inhibitory-related processes in non-human primates as well as humans with ADHD, tic disorders and neurodegenerative disorders (Arnsten and Li, 2005; Gau and Shang, 2010; Hunt et al., 1995; Jakala et al., 1999a; Scahill et al., 2001; Shang and Gau, 2012; Swartz et al., 2008;…”
Metadata
- Authors
- Ye, Z., Altena, E., Nombela, C., Housden, C. R., Maxwell, H., Rittman, T., Huddleston, C., Rae, C. L., Regenthal, R., Sahakian, B. J., Barker, R. A., Robbins, T. W., & Rowe, J. B.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 77
- Issue
- 8
- Pages
- 740-748
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2058481315
- Cited by
- 105
- References
- 26
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.